Scarica l'app Stockscreener
1.87
3.11%
-0.06
Dopo l'orario di chiusura:
1.96
0.09
+4.81%
Nrx Pharmaceuticals Inc Borsa (NRXP) Ultime notizie
NRx Pharmaceuticals CEO Sets to Reveal Growth Strategy at Exclusive H.C. Wainwright Discussion - Stock Titan
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Definitive Purchase Agreement with Dura Medical; Initial Acquisition for Planned International Network of Interventional Psychiatry Clinics (PR Newswire) - Aktiellt
NRx Pharmaceuticals increases at-the-market offering to $20M - Investing.com Australia
NRx Pharmaceuticals increases at-the-market offering to $20M By Investing.com - Investing.com Canada
Press Release Distribution & PR Platform - ACCESS Newswire
HOPE Therapeutics secures $2.5 million investment By Investing.com - Investing.com South Africa
Large Strategic Investment from Global Medical Device Manufacturer to Support Clinics Treating Suicidal Depression and PTSD with Groundbreaking Drugs and Modalities: $NRXP - The Globe and Mail
Hope Therapeutics And Nrx Pharma Announce Signing Of A Term Sheet For Strategic Investment From A Global Medical Device Manufacturer - MarketScreener
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of a Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE - Morningstar
BTIG Initiates Coverage of NRx Pharmaceuticals (NRXP) with Buy Recommendation - Nasdaq
BTIG initiates NRx Pharmaceuticals with $18 price target By Investing.com - Investing.com Australia
BTIG initiates NRx Pharmaceuticals with $18 price target - Investing.com
HOPE Therapeutics expands with Dura Medical acquisition By Investing.com - Investing.com Canada
NRx Pharmaceuticals' Hope Therapeutics to acquire Dura Medical, no terms - MSN
NRx Pharma: HOPE Therapeutics Signs Deal To Buy Dura Medical - Nasdaq
HOPE Therapeutics expands with Dura Medical acquisition - Investing.com
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Definitive Purchase Agreement with Dura Medical; Initial Acquisition for Planned International Network of Interventional Psychiatry Clinics - The Victoria Advocate
Here's Why NRx Pharmaceuticals (NRXP) Is a Great 'Buy the Bottom' Stock Now - MSN
HOPE Therapeutics set to acquire majority of Neurospa By Investing.com - Investing.com Australia
$300 Million in Milestones; Double-Digit Royalties; LOI with - openPR.com
NRx Pharmaceuticals Unit Signs Letter of Intent to Acquire Neurospa TMS -March 24, 2025 at 08:43 am EDT - MarketScreener
HOPE Therapeutics and NRx Pharmaceuticals Sign Binding Letter of Intent with Neurospa TMS Holdings - MarketScreener
HOPE Therapeutics set to acquire majority of Neurospa - Investing.com
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Letter of Intent with Neurospa TMS Holdings, LLC for Expansion of its Planned International Network of Interventional Psychiatry Clinics - Longview News-Journal
NRX Pharmaceuticals Reports 2024 Financial Results and Strategy - TipRanks
Psychedelic: atai Life Sciences, NRx report quarterly results - Yahoo Finance
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q4 2024 Earnings Call Transcript - Insider Monkey
H.C. Wainwright maintains $19 target on NRx Pharmaceuticals stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $19 target on NRx Pharmaceuticals stock - Investing.com
NRx Pharmaceuticals submits NDA for intravenous ketamine drug - Mugglehead Magazine
NRx pharmaceuticals files New Drug Application for ketamine depression treatment - Green Market Report
NRx Pharmaceuticals (NRXP) to Release Quarterly Earnings on Wednesday - Defense World
NRX Pharmaceuticals Inc (NRXP) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial ... By GuruFocus - Investing.com Canada
NRx Pharmaceuticals Reports Progress in Drug Development and Strategic Expansion - TipRanks
NRx Pharmaceuticals’ Earnings Call: Progress Amid Challenges - TipRanks
$300 Million in Milestones Plus Tiered Double-Digit Royalties from Accepted Terms to License and Distribute NRX-100 Drug: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - Barchart
$300 Million in Milestones Plus Tiered Double-Digit Royalties - openPR
Earnings call transcript: NRx Pharmaceuticals sees stock dip despite cost cuts in Q4 2024 By Investing.com - Investing.com South Africa
NRX Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: NRx Pharmaceuticals sees stock dip despite cost cuts in Q4 2024 - Investing.com
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - PR Newswire
INVESTOR ALERT: Kaskela Law LLC Announces Investigation of NRx Pharmaceuticals, Inc. and Encourages Long-Term NRXP / BRPA Investors to Contact the Firm - ACCESS Newswire
NRX Pharmaceuticals, Inc. SEC 10-K Report - TradingView
NRX Pharmaceuticals Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
0.15%
4.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):